Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Standard
Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. / Den, Boer; Harms, [Unbekannt]; Pieters, R; Kazemier, [Unbekannt]; Gobel, U; Körholz, D; Graubner, U; Haas, [Unbekannt]; Jorch, N; Spaar, [Unbekannt]; Kaspers, [Unbekannt]; Kamps, [Unbekannt]; Does, Van der; Berg, Van den; Wering, Van; Janka-Schaub, Gritta; Janka-Schaub, [Unbekannt].
in: J CLIN ONCOL, Jahrgang 21, Nr. 17, 17, 2003, S. 3262-3268.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
AU - Den, Boer
AU - Harms, [Unbekannt]
AU - Pieters, R
AU - Kazemier, [Unbekannt]
AU - Gobel, U
AU - Körholz, D
AU - Graubner, U
AU - Haas, [Unbekannt]
AU - Jorch, N
AU - Spaar, [Unbekannt]
AU - Kaspers, [Unbekannt]
AU - Kamps, [Unbekannt]
AU - Does, Van der
AU - Berg, Van den
AU - Wering, Van
AU - Janka-Schaub, Gritta
AU - Janka-Schaub, [Unbekannt]
PY - 2003
Y1 - 2003
N2 - PURPOSE: To confirm the prognostic value of a drug resistance profile combining prednisolone, vincristine, and l-asparaginase (PVA) cytotoxicity in an independent group of children with acute lymphoblastic leukemia (ALL) treated with a different protocol and analyzed at longer follow-up compared with our previous study of patients treated according to the Dutch Childhood Leukemia Study Group (DCLSG) ALL VII/VIII protocol. PATIENTS AND METHODS: Drug resistance profiles were determined in 202 children (aged 1 to 18 years) with newly diagnosed ALL who were treated according to the German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL)-92 protocol. RESULTS: At a median follow-up of 6.2 years (range, 4.1 to 9.3 years), the 5-year disease-free survival probability (pDFS) rate +/- SE was 69% +/- 7.0%, 83% +/- 4.4%, and 84% +/- 6.8% for patients with resistant (PVA score 7 to 9), intermediate-sensitive (PVA score 5 to 6), and sensitive (SPVA score 3 to 4) profiles, respectively (sensitive and intermediate-sensitive v resistant, P
AB - PURPOSE: To confirm the prognostic value of a drug resistance profile combining prednisolone, vincristine, and l-asparaginase (PVA) cytotoxicity in an independent group of children with acute lymphoblastic leukemia (ALL) treated with a different protocol and analyzed at longer follow-up compared with our previous study of patients treated according to the Dutch Childhood Leukemia Study Group (DCLSG) ALL VII/VIII protocol. PATIENTS AND METHODS: Drug resistance profiles were determined in 202 children (aged 1 to 18 years) with newly diagnosed ALL who were treated according to the German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL)-92 protocol. RESULTS: At a median follow-up of 6.2 years (range, 4.1 to 9.3 years), the 5-year disease-free survival probability (pDFS) rate +/- SE was 69% +/- 7.0%, 83% +/- 4.4%, and 84% +/- 6.8% for patients with resistant (PVA score 7 to 9), intermediate-sensitive (PVA score 5 to 6), and sensitive (SPVA score 3 to 4) profiles, respectively (sensitive and intermediate-sensitive v resistant, P
M3 - SCORING: Zeitschriftenaufsatz
VL - 21
SP - 3262
EP - 3268
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 17
M1 - 17
ER -
